Clincosm LogoSign in Get a demo

tyrosine kinase inhibitor

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
  • Thyroid Cancer
  • +2 more
  • Tyrosine kinase inhibitor drugs.
  • Fuzhou, Fujian, China
    Road Fuma No.420
Apr 11, 2023

Cancer, Cancer, Treatment-Related, Medication Adherence Trial in Chicago (Oncotool Intervention (symptom reporting + TKI

Completed
  • Cancer
  • +4 more
  • Oncotool Intervention (symptom reporting + TKI education)
  • Oncotool Control (health information)
  • Chicago, Illinois
    Northwestern University
Jan 25, 2023

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

NSCLC, Bevacizumab, EGF-R Positive NSCLC Trial in Tianjin (Bevacizumab, Icotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Mar 2, 2022

Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

Not yet recruiting
  • Tyrosine Kinase Inhibitor
  • +2 more
    • Taipei, Taiwan
      National Taiwan University Hospital
    Feb 17, 2022

    Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

    Recruiting
    • Non Small Cell Lung Cancer
    • +2 more
      • Rotterdam, Netherlands
        Erasmus MC
      Feb 2, 2022

      Ovarian Tumors, Fallopian Tube Tumors, Tumors by Site Trial (Drug: Anlotinib, Drug: Carboplatin/Paclitaxel)

      Not yet recruiting
      • Ovarian Neoplasms
      • +14 more
      • Drug: Anlotinib
      • Drug: Carboplatin/Paclitaxel
      • (no location specified)
      Mar 17, 2021